Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Bruce Cree(University of California, San Francisco), Nadia Tenenbaum(Merck Serono S.p.A. (Italy)), Andrija Javor(Merck KGaA, Darmstadt (Germany)), Patrick Vermersch(Inserm), Olaf Stüve(Southwestern Medical Center), Yann Hyvert(Merck KGaA, Darmstadt (Germany)), Frank Dahlke(Ophthalmology Clinic), Heinz Wiendl(University Medical Center Freiburg), Davorka Tomic(Multiple Sclerosis Research Institute), Hans Guehring(Merck KGaA, Darmstadt (Germany)), Ludwig Kappos(University Hospital of Basel), Douglas L. Arnold(McGill University), Claire Le Bolay(Merck Serono S.A.S. (France)), Eva Havrdová(Charles University), Li Shen Loo(Merck Serono S.p.A. (Italy)), Anne H. Cross(Washington University in St. Louis), Sathej Gopalakrishnan(Merck KGaA, Darmstadt (Germany)), Jerry S. Wolinsky
Cited by 74
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k